Evidence map›Paper›PMID 34185801›Full record

SynthesisPloS one2021

Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis.

Ana Karla G Melo, Keilla M Milby, Ana Luiza M A Caparroz, Ana Carolina P N Pinto, Rodolfo R P Santos, Aline P Rocha, Gilda A Ferreira, Viviane A Souza, Lilian D A Valadares, Rejane M R A Vieira and 2 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 3 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 3 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. The I/D variant of theFuture science OA · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 2 countries.

Ana Karla G MeloDivision of Rheumatology, Department of Clinical Medicine, Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, PB, Brazil.
Keilla M MilbyEvidence-Based Health Program, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Ana Luiza M A CaparrozEvidence-Based Health Program, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Ana Carolina P N PintoEvidence-Based Health Program, Universidade Federal de São Paulo, São Paulo, SP, Brazil.ORCID 0000-0002-1505-877X
Rodolfo R P SantosEvidence-Based Health Program, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Aline P RochaEvidence-Based Health Program, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Gilda A FerreiraDepartment of Lokomotor System, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Viviane A SouzaDepartment of Clinical Medicine, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.
Lilian D A ValadaresDepartment of Rheumatology, Hospital Getúlio Vargas de Pernambuco, Recife, PE, Brazil.
Rejane M R A VieiraDepartment of Clinical Medicine, Universidade Estadual do Ceará, Fortaleza, CE, Brazil.ORCID 0000-0003-4475-6064
Gecilmara S PileggiDepartment of Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Virgínia F M TrevisaniEvidence-Based Health Program, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Universidade Federal de São Paulo · BRFaculdade de Medicina de São José do Rio Preto · BRFundação Getulio Vargas · BRUniversidade de Santo Amaro · BRUniversidade Estadual do Ceará · BRUniversidade Federal da Paraíba · BRUniversidade Federal de Juiz de Fora · BRUniversidade Federal de Minas Gerais · BRUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe the laboratory parameters and biomarkers of the cytokine storm syndrome associated with severe and fatal COVID-19 cases.

methodsA search with standardized descriptors and synonyms was performed on November 28th, 2020 of the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, LILACS, and IBECS to identify studies of interest. Grey literature searches and snowballing techniques were additionally utilized to identify yet-unpublished works and related citations. Two review authors independently screened the retrieved titles and abstracts, selected eligible studies for inclusion, extracted data from the included studies, and then assessed the risk of bias using the Newcastle-Ottawa Scale. Eligible studies were those including laboratory parameters-including serum interleukin-6 levels-from mild, moderate, or severe COVID-19 cases. Laboratory parameters, such as interleukin-6, ferritin, hematology, C-Reactive Protein, procalcitonin, lactate dehydrogenase, aspartate aminotransferase, creatinine, and D-dimer, were extracted from the studies. Meta-analyses were conducted using the laboratory data to estimate mean differences with associated 95% confidence intervals. DATA SYNTHESIS: The database search yielded 9,620 records; 40 studies (containing a total of 9,542 patients) were included in the final analysis. Twenty-one studies (n = 4,313) assessed laboratory data related to severe COVID-19 cases, eighteen studies (n = 4,681) assessed predictors for fatal COVID-19 cases and one study (n = 548) assessed laboratory biomarkers related to severe and fatal COVID-19 cases. Lymphopenia, thrombocytopenia, and elevated levels of interleukin-6, ferritin, D-dimer, aspartate aminotransferase, C-Reactive-Protein, procalcitonin, creatinine, neutrophils and leucocytes were associated with severe and fatal COVID-19 cases.

conclusionsThis review points to interleukin-6, ferritin, leukocytes, neutrophils, lymphocytes, platelets, C-Reactive Protein, procalcitonin, lactate dehydrogenase, aspartate aminotransferase, creatinine, and D-dimer as important biomarkers of cytokine storm syndrome. Elevated levels of interleukin-6 and hyperferritinemia should be considered as red flags of systemic inflammation and poor prognosis in COVID-19.

Indexed as

BiomarkersCOVID-19C-Reactive ProteinCytokine Release SyndromeFerritinsHumansInterleukin-6LeukocytesSARS-CoV-2Severity of Illness IndexBiomarkersC-Reactive ProteinFerritinsInterleukin-6

Identifiers

PMID34185801
PMCPMC8241122
OpenAlexW3174033189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.